Multivariable analysis of transplantation outcomes
| Variables . | Overall survival . | Treatment-related mortality . | Disease-associated mortality . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Number* . | Hazard ratio (95% CI) . | P . | Number* . | Hazard ratio (95% CI) . | P . | Number* . | Hazard ratio (95% CI) . | P . | |
| Age group, y | |||||||||
| 50 or younger | 109/177 | 1.00 | Reference | 70/173 | 1.00 | Reference | 35/173 | 1.00 | Reference |
| Older than 50 | 152/209 | 1.56 (1.14-2.12) | .005 | 91/203 | 1.40 (0.96-2.05) | .084 | 55/203 | 1.22 (0.71-2.10) | .465 |
| Sex of recipient† | |||||||||
| Female | 105/177 | 1.00 | Reference | 68/171 | - | - | 31/171 | 1.00 | Reference |
| Male | 156/209 | 1.37 (1.07-1.77) | .014 | 93/205 | - | - | 59/205 | 1.86 (1.17-2.95) | .008 |
| Disease status | |||||||||
| Complete remission | 60/118 | 1.00 | Reference | 43/117 | 1.00 | Reference | 16/117 | 1.00 | Reference |
| Not in complete remission | 184/246 | 2.01 (1.50-2.71) | < .001 | 106/238 | 1.30 (0.92-1.84) | .137 | 70/238 | 2.55 (1.50-4.33) | .001 |
| Unknown | 17/22 | 2.01 (1.15-3.50) | .014 | 12/21 | 1.74 (0.89-3.40) | .105 | 4/21 | 1.42 (0.45-4.52) | .554 |
| Conditioning regimen | |||||||||
| CY-TBI or BU-CY | 68/114 | 1.00 | Reference | 45/112 | 1.00 | Reference | 21/112 | 1.00 | Reference |
| Purine analog–containing | 136/196 | 1.05 (0.75-1.48) | .777 | 79/191 | 0.86 (0.56-1.32) | .487 | 52/191 | 1.34 (0.72-2.48) | .360 |
| Others | 57/76 | 1.26 (0.86-1.84) | .240 | 37/73 | 1.23 (0.78-1.95) | .377 | 17/73 | 1.10 (0.56-2.13) | .784 |
| GVHD prophylaxis‡ | |||||||||
| Cyclosporine-based | 160/246 | 1.00 | Reference | 99/241 | 1.00 | Reference | 56/241 | 1.00 | Reference |
| Tacrolimus-based | 91/130 | 1.09 (0.78-1.51) | .614 | 55/127 | 1.13 (0.72-1.75) | .599 | 33/127 | 1.05 (0.57-1.93) | .887 |
| Others | 10/10 | 1.74 (0.89-3.42) | .105 | 7/8 | 2.29 (1.14-4.62) | .020 | 1/8 | 0.32 (0.04-2.42) | .268 |
| Type of graft source | |||||||||
| Matched related bone marrow or peripheral blood | 92/154 | 1.00 | Reference | 57/149 | 1.00 | Reference | 30/149 | 1.00 | Reference |
| Mismatched related bone marrow or peripheral blood | 32/43 | 1.55 (0.98-2.45) | .063 | 18/42 | 1.12 (0.59-2.12) | .722 | 13/42 | 1.50 (0.67-3.37) | .329 |
| Unrelated bone marrow | 63/99 | 1.24 (0.82-1.88) | .312 | 41/99 | 1.19 (0.71-1.98) | .512 | 22/99 | 1.06 (0.46-2.48) | .888 |
| Unrelated cord blood | 74/90 | 2.08 (1.43-3.02) | < .001 | 45/86 | 1.77 (1.10-2.86) | .019 | 25/86 | 1.49 (0.80-2.80) | .211 |
| Time from diagnosis to transplantation | |||||||||
| 6 months or less | 128/189 | 1.00 | Reference | 81/183 | 1.00 | Reference | 41/183 | 1.00 | Reference |
| More than 6 months | 125/184 | 1.03 (0.78-1.35) | .834 | 76/180 | 0.86 (0.61-1.22) | .395 | 45/180 | 1.32 (0.82-2.12) | .258 |
| Uncertain/missing | 8/13 | 1.01 (0.49-2.09) | .971 | 4/13 | 0.64 (0.25-1.60) | .340 | 4/13 | 1.93 (0.77-4.87) | .163 |
| Year of transplantation | |||||||||
| 1995-1999 | 18/24 | 1.00 | Reference | 11/24 | 1.00 | Reference | 7/24 | 1.00 | Reference |
| 2000-2002 | 85/119 | 1.01 (0.58-1.74) | .979 | 56/113 | 1.13 (0.59-2.13) | .716 | 23/113 | 0.61 (0.26-1.46) | .269 |
| 2003-2005 | 158/243 | 0.73 (0.41-1.32) | .296 | 94/239 | 0.75 (0.37-1.51) | .416 | 60/239 | 0.70 (0.29-1.73) | .442 |
| Variables . | Overall survival . | Treatment-related mortality . | Disease-associated mortality . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Number* . | Hazard ratio (95% CI) . | P . | Number* . | Hazard ratio (95% CI) . | P . | Number* . | Hazard ratio (95% CI) . | P . | |
| Age group, y | |||||||||
| 50 or younger | 109/177 | 1.00 | Reference | 70/173 | 1.00 | Reference | 35/173 | 1.00 | Reference |
| Older than 50 | 152/209 | 1.56 (1.14-2.12) | .005 | 91/203 | 1.40 (0.96-2.05) | .084 | 55/203 | 1.22 (0.71-2.10) | .465 |
| Sex of recipient† | |||||||||
| Female | 105/177 | 1.00 | Reference | 68/171 | - | - | 31/171 | 1.00 | Reference |
| Male | 156/209 | 1.37 (1.07-1.77) | .014 | 93/205 | - | - | 59/205 | 1.86 (1.17-2.95) | .008 |
| Disease status | |||||||||
| Complete remission | 60/118 | 1.00 | Reference | 43/117 | 1.00 | Reference | 16/117 | 1.00 | Reference |
| Not in complete remission | 184/246 | 2.01 (1.50-2.71) | < .001 | 106/238 | 1.30 (0.92-1.84) | .137 | 70/238 | 2.55 (1.50-4.33) | .001 |
| Unknown | 17/22 | 2.01 (1.15-3.50) | .014 | 12/21 | 1.74 (0.89-3.40) | .105 | 4/21 | 1.42 (0.45-4.52) | .554 |
| Conditioning regimen | |||||||||
| CY-TBI or BU-CY | 68/114 | 1.00 | Reference | 45/112 | 1.00 | Reference | 21/112 | 1.00 | Reference |
| Purine analog–containing | 136/196 | 1.05 (0.75-1.48) | .777 | 79/191 | 0.86 (0.56-1.32) | .487 | 52/191 | 1.34 (0.72-2.48) | .360 |
| Others | 57/76 | 1.26 (0.86-1.84) | .240 | 37/73 | 1.23 (0.78-1.95) | .377 | 17/73 | 1.10 (0.56-2.13) | .784 |
| GVHD prophylaxis‡ | |||||||||
| Cyclosporine-based | 160/246 | 1.00 | Reference | 99/241 | 1.00 | Reference | 56/241 | 1.00 | Reference |
| Tacrolimus-based | 91/130 | 1.09 (0.78-1.51) | .614 | 55/127 | 1.13 (0.72-1.75) | .599 | 33/127 | 1.05 (0.57-1.93) | .887 |
| Others | 10/10 | 1.74 (0.89-3.42) | .105 | 7/8 | 2.29 (1.14-4.62) | .020 | 1/8 | 0.32 (0.04-2.42) | .268 |
| Type of graft source | |||||||||
| Matched related bone marrow or peripheral blood | 92/154 | 1.00 | Reference | 57/149 | 1.00 | Reference | 30/149 | 1.00 | Reference |
| Mismatched related bone marrow or peripheral blood | 32/43 | 1.55 (0.98-2.45) | .063 | 18/42 | 1.12 (0.59-2.12) | .722 | 13/42 | 1.50 (0.67-3.37) | .329 |
| Unrelated bone marrow | 63/99 | 1.24 (0.82-1.88) | .312 | 41/99 | 1.19 (0.71-1.98) | .512 | 22/99 | 1.06 (0.46-2.48) | .888 |
| Unrelated cord blood | 74/90 | 2.08 (1.43-3.02) | < .001 | 45/86 | 1.77 (1.10-2.86) | .019 | 25/86 | 1.49 (0.80-2.80) | .211 |
| Time from diagnosis to transplantation | |||||||||
| 6 months or less | 128/189 | 1.00 | Reference | 81/183 | 1.00 | Reference | 41/183 | 1.00 | Reference |
| More than 6 months | 125/184 | 1.03 (0.78-1.35) | .834 | 76/180 | 0.86 (0.61-1.22) | .395 | 45/180 | 1.32 (0.82-2.12) | .258 |
| Uncertain/missing | 8/13 | 1.01 (0.49-2.09) | .971 | 4/13 | 0.64 (0.25-1.60) | .340 | 4/13 | 1.93 (0.77-4.87) | .163 |
| Year of transplantation | |||||||||
| 1995-1999 | 18/24 | 1.00 | Reference | 11/24 | 1.00 | Reference | 7/24 | 1.00 | Reference |
| 2000-2002 | 85/119 | 1.01 (0.58-1.74) | .979 | 56/113 | 1.13 (0.59-2.13) | .716 | 23/113 | 0.61 (0.26-1.46) | .269 |
| 2003-2005 | 158/243 | 0.73 (0.41-1.32) | .296 | 94/239 | 0.75 (0.37-1.51) | .416 | 60/239 | 0.70 (0.29-1.73) | .442 |
CI indicates confidence interval; GVHD, graft-versus-host disease; CY-TBI, cyclophosphamide with total-body irradiation; BU-CY, busulfan and cyclophosphamide; purine analog–containing, regimens containing fludarabine, cladribine or pentostatin; cyclosporine-based, cyclosporine with or without other agents; tacrolimus-based, tacrolimus with or without other agents; and Reference, reference category in regression models.
Number of events/number of evaluable patients.
Sex of recipient was not included as a confounder in the multivariable final model for treatment-related mortality because it was not found to be a significant factor in univariable comparison.
GVHD prophylaxis other than cyclosporine- or tacrolimus-based regimen was not considered as a significant variable associated with treatment-related mortality because of the small number of patients in this group.